Evofosfamide
Evofosfamide
Evofosfamide (pronounced as e-voe-fos-fa-mide), also known as TH-302, is an investigational hypoxia-activated prodrug that is selectively activated under severe hypoxic conditions, a common feature of many types of solid tumors.
Etymology
The name "Evofosfamide" is derived from the words "Evo" (short for evolution) and "fosfamide" (a class of alkylating agents used in cancer treatment). The term "TH-302" is an abbreviation of the original compound name given by the developers.
Mechanism of Action
Evofosfamide is designed to be activated under hypoxic conditions, where it releases a DNA crosslinking agent, bromo-isophosphoramide mustard (Br-IPM). This leads to DNA damage and cell death in hypoxic tumor cells. The drug is inactive in normal, oxygenated tissues, reducing the potential for systemic toxicity.
Clinical Trials
Evofosfamide has been studied in several clinical trials for the treatment of various types of cancer, including pancreatic cancer, soft tissue sarcoma, and non-small cell lung cancer. However, in 2016, the drug failed to meet its primary endpoints in two Phase III trials, leading to a halt in its development.
Related Terms
- Hypoxia (medical)
- Prodrug
- Alkylating antineoplastic agent
- Clinical trial
- Pancreatic cancer
- Soft tissue sarcoma
- Non-small cell lung cancer
External links
- Medical encyclopedia article on Evofosfamide
- Wikipedia's article - Evofosfamide
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski